Business Analysts Start to Pay Attention to the Longevity Industry

Larger business analysis concerns are starting to notice that the longevity industry exists. I point out this press release not because the contents are all that interesting or useful - it is very much business as usual in the white paper production community, and the people creating these materials typically have a poor understanding of the biology and the biotechnology - but rather as an indication of progress towards a broader appreciation of the potential to treat aging as a medical condition. Slowly, the eyes of the world are opened.

The global longevity and anti-senescence market will witness rapid growth over the forecast period (2018-2023) owing to an increasing emphasis on stem cell research and increasing demand for cell-based assays in research and development. An increasing geriatric population across the globe and rising awareness of antiaging products among generation Y and later generations are the major factors expected to promote the growth of a global longevity and anti-senescence market. Factors such as a surging level of disposable income and increasing advancements in anti-senescence technologies are also providing traction to the global longevity and anti-senescence market growth over the forecast period (2018-2023).

Senolytics, placenta stem cells, and blood transfusions are some of the hot technologies picking up pace in the longevity and anti-anti-senescence market. Companies and start-ups across the globe such as Unity Biotechnology, Human Longevity Inc., Calico Life Sciences, Acorda Therapeutics, etc. are working extensively in this field for the extension of human longevity by focusing on the study of genomics, microbiome, bioinformatics, and stem cell therapies, etc. Senolytic drug therapy held the largest market revenue share in 2017. The fastest growth of the gene therapy segment is due to the large investments in genomics.

The scope of this report is broad and covers various therapies currently under trials in the global longevity and anti-senescence therapy market. The market estimation has been performed with consideration for revenue generation in the forecast years 2018-2023 after the expected availability of products in the market by 2023. The global longevity and anti-senescence therapy market has been segmented by the following therapies: senolytic drug therapy, gene therapy, immunotherapy, and other therapies which includes stem cell-based therapies, etc. Forecasts from 2028 to 2023 are given for each therapy and application, with estimated values derived from the expected revenue generation in the first year of launch.



I wonder when Oisin will get to human clinical trials with their senoltyic product? I understand that they are focusing on cancer and p53 first.

One interesting thing they could do with their neutral lippose delivery technology other than just a suicide gene linked to the p53 promotor would be to put the newly announced CRISPRa MAEGI system inside their lipposomes, it should only upregulate cancer neoantigens and leave other cells of the body alone, could be much easier than infecting CRISPRa in an AAV vector directly into the tumor site.

Posted by: jimofoz at October 17th, 2019 6:21 AM

@jimofoz We're right now working on raising the required funds to accelerate our p16-based senolytic therapy to the clinic; depending on funding, a second clinical trial following the p53 cancer trial could be begun about 6 months after the oncology Phase 1.

I can't address the idea you mention directly, but I will say that the immuno-oncology aspects of our LNP delivery technology have not escaped our notice. But the pace of progress is and will be dependent upon funding.

Posted by: Gary at October 17th, 2019 10:04 AM

Thanks for the update Gary.

Regarding targeting your fusogenix lipposomes to specific cell types based on their surface markers - I remember reading about those DNA nanocages which are held shut by two aptamers, but one of the aptamers has a much higher affinity for an antigen of choice, so that cage opens in the presence of that antigen.

Could you somehow anchor one end of an aptamer into the lipid bilayer of your lipposome and have the other end have some affinity to the fusogenix protein, but higher affinity to a cell surface protein of choice? That way when your lipposome may much more selectively fuse with those cells as the fusogenix proteins are only unbound in the presence of those cell proteins? (of course free floating protein could be a problem).

Posted by: jimofoz at October 18th, 2019 10:43 AM

Our therapeutics currently target only based on transitional activity within a cell, but it is true that the same LNPs have been used with "decorations" on their surface to be more selective with respect to the types of cell they fuse with. That research approach used fairly conventional agents to promote selectivity. But we always want the fusogenic protein to be deeply embedded into the LNP membrane; I am not enough of an expert to describe why, sorry, plus we get into IP issues that I can't discuss.

Posted by: Gary at October 18th, 2019 12:18 PM
Comment Submission

Post a comment; thoughtful, considered opinions are valued. New comments can be edited for a few minutes following submission. Comments incorporating ad hominem attacks, advertising, and other forms of inappropriate behavior are likely to be deleted.

Note that there is a comment feed for those who like to keep up with conversations.